BUSULFAN AND TOTAL-BODY IRRADIATION AS ANTIHEMATOPOIETIC STEM-CELL AGENTS IN THE PREPARATION OF PATIENTS WITH CONGENITAL BONE-MARROW DISORDERS FOR ALLOGENEIC BONE-MARROW TRANSPLANTATION

  • 1 January 1984
    • journal article
    • research article
    • Vol. 64  (4) , 852-857
Abstract
The capacity of busulfan and total body irradiation to ablate hematopoietic stem cells as preparation for the allogeneic bone marrow transplantation of patients with congenital bone marrow disorders was studied. Patients [14] received 18 transplants; busulfan was used in the preparatory regimen of 8 transplants and total body irradiation in the regimens of 6 transplants. Sustained hematopoietic ablation was achieved in 6 of 8 patients prepared with busulfan and in all 6 patients prepared with total body irradiation. Three patients prepared with total body irradiation died with idiopathic interstitial pneumonitis, whereas no patients receiving busulfan developed interstitial pneumonitis. The optimal antihematopoietic stem cell agent to be used for the preparation of patients with congenital bone marrow disorder for bone marrow transplantation is not certain.